三重利好驱动：创新药BD迭起+业绩高增+流动性改善，港股通创新药ETF易方达(159316)涨2.89%，港股通医药ETF易方达(513200)涨2.33%

Group 1 - The Hong Kong stock market for innovative drugs is experiencing an upward trend, with the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) rising by 2.89% and the E Fund Hong Kong Stock Connect Medical ETF (513200) increasing by 2.33% [1] - The rebound in the sector is driven by three main factors: a surge in business development (BD) transactions, high growth performance forecasts, and improved liquidity [1] - Significant BD transactions in innovative drugs include a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca on January 30, and an $8.85 billion partnership between Innovent Biologics and Eli Lilly on February 8, marking record high upfront payments for Chinese pharmaceutical companies [1] Group 2 - The performance forecasts for innovative drug companies indicate a positive industry outlook, with Innovent Biologics, Rongchang Biologics, and Junshi Biosciences projecting revenues of approximately 11 billion, 3.25 billion, and 2.5 billion yuan for 2025, representing year-on-year growth of 45%, 89%, and 31.8% respectively [1] - Guotai Junan Securities anticipates a performance disclosure window for innovative drug companies in February and March, with several firms expected to reduce losses or turn profitable, and predicts that more companies will achieve profitability in 2026 [1] - Upcoming academic conferences such as AACR in April, ASCO in May, and ESMO in October are expected to further validate clinical data for domestic innovative drugs, indicating a clear upward trend in the industry [1] Group 3 - The E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) is currently the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, focusing on core enterprises in the innovative drug industry and excluding CXO companies [2] - The E Fund Hong Kong Stock Connect Medical ETF (513200) tracks a broader medical index, covering key areas such as innovative drugs, medical devices, and medical services, with a total size of 1.695 billion yuan, making it the largest among similar ETFs [2] - The comprehensive fee rate for the E Fund Hong Kong Stock Connect Medical ETF is 0.2% per year, the lowest in its category, and it supports T+0 trading [2]